P2Y12 Platelet Inhibitor drugs compared

Compare all 5 P2Y12 Platelet Inhibitor drugs side by side. They share one FDA-defined mechanism but differ in approved uses, prescription status, brand-vs-generic options, price, and FDA recall-safety record — which our independent rating scores. The highest-rated is effient.

Top-rated p2y12 platelet inhibitor: 1. Effient · 2. Kengreal · 3. Plavix

P2Y12 Platelet Inhibitor drugs compared side by side, with pharmaranks' FDA recall-safety rating
Drug	Generic	Form	Status	Used for	Safety ratingFDA recall-based	Pharmacy pays
Effient	Prasugrel Hydrochloride	Tablet	Prescription	—	70/100	$9
Kengreal	Cangrelor	Injectable	Prescription	—	70/100	—
Plavix	Clopidogrel Bisulfate	Tablet	Prescription	—	70/100	—
Clopidogrel Bisulfate	—	Tablet	Prescription	—	66/100	—
Cangrelor	—	Injectable	Prescription	—	Not yet rated	—

The safety rating column is unique to pharmaranks — an independent 0–100 score from FDA regulatory recall data. Higher is safer. Not medical advice.

Full ranking · 5 drugs

Frequently asked questions

What is the P2Y12 Platelet Inhibitor drug class?

P2Y12 Platelet Inhibitor is an FDA Established Pharmacologic Class (EPC) — a group of drugs that share a mechanism of action. pharmaranks lists 5 P2Y12 Platelet Inhibitor products, each independently rated.

Are all P2Y12 Platelet Inhibitor drugs the same?

No. P2Y12 Platelet Inhibitor drugs share the same core mechanism — that is why they sit in one FDA class — but they differ in their approved uses, available forms, whether they are prescription or over-the-counter, brand-vs-generic options and price, and their FDA recall-safety record.

Which P2Y12 Platelet Inhibitor drug is best-rated?

By our independent rating, effient currently ranks highest among P2Y12 Platelet Inhibitor drugs. Ratings are based on FDA regulatory (recall-safety) data — always consult a professional.

Sources: the P2Y12 Platelet Inhibitor class definition and its member drugs come from the U.S. NLM RxClass (Established Pharmacologic Class). Ratings are pharmaranks’ independent FDA recall-safety analysis.